Tag: CADENZA trial
-
FDA Approves Decnupaz, the First Antibody-Drug Conjugate for Blastic Plasmacytoid Dendritic Cell Neoplasm
The U.S. Food and Drug Administration has approved Decnupaz (pivekimab sunirine-pvzy), marking a major step forward for people facing blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is an extremely rare and aggressive blood cancer that has historically offered patients very few effective treatment options. With this approval, adults diagnosed with BPDCN – whether newly…